IL1B and breast carcinoma: The molecular mechanism of the inhibitory action is the activation of the STAT1/inducible nitric oxide synthase (iNOS)/reactive oxygen species (ROS) axis; M1 secretes IL-1β, leading to breast cancer senescence (Fig. 3A).97